VICM as a risk marker of kidney disease progression in people with type 2 diabetes

VICM, a biomarker of macrophage-driven inflammation, as a risk marker of kidney disease progression in people with type 2 diabetes

Introduction

Hyperglycemia-induced metabolic stress promotes macrophage recruitment, driving inflammation, fibrosis, and kidney damage. Early biomarkers that can serve as risk markers for progression of diabetic kidney disease (DKD) are needed. We investigated whether circulating VICM—a fragment of citrullinated, MMP-degraded vimentin—is a risk marker for progression of DKD in people with type 2 diabetes (T2D) and moderately increased albuminuria.

Poster

Conclusion

Higher VICM is an independent risk marker of DKD progression in people with T2D. Biomarkers reflecting macrophage-driven immune dysregulation, such as VICM, may enable early identification of people at high risk of kidney complications.

Get in touch

Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.

+45 4452 5252 Contact us via email!

Your scientific area Select areaAgingCardiovascularDermatologyDiabetesGastroenterologyHepatologyKidneyRespiratoryNeuroscienceObesityOncologyRheumatologyClinical Laboratory services Your request Select requestGeneral inquiryBiomarkersLaboratorySomething else

First name Last name

Email Company/Organization Phone (optional) Your message (optional) Where did you hear about us? (optional) Select optionGoogleLinkedInWebinarNordic Bioscience RepresentativeConference / EventColleague / RecommendationWebsite Nordic Bioscience ApS and its non-profit partner, The Extracellular Matrix Pharmacology Congress, can contact me by email with news on research, events, products, and similar. I can always withdraw my consent at any time. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.